Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07607587 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
NCT07607587 is a Phase 1 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 114 participants.
The verdict
NCT07607587, a Phase 1 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Interventions
- DRUG Cagrilintide
- DRUG Placebo (matched to Cagrilintide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2026-05-29 |
| Est. Completion | 2027-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07607587
The ClinicalTrials.gov registry entry for NCT07607587 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cagrilintide is the first listed.
NCT07607587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07607587 about?
NCT07607587 is a clinical study titled "Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events". The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being t...
What is the current status of trial NCT07607587?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2026-05-29. Estimated completion is 2027-11-19.
What interventions are being tested in trial NCT07607587?
The interventions under investigation include: Cagrilintide (DRUG), Placebo (matched to Cagrilintide) (DRUG).
Who is sponsoring clinical trial NCT07607587?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.